Welcome to Library
Annual Reports
RMRIMS News Bulletine
 
Publications List of Dr. Vidya Nand Ravi Das

 

109
Amit A, Vijayamahantesh, Dikhit MR, Singh AK, Kumar V, Suman SS, Singh A, Kumar A, Thakur AK, Das VR, Das P and Bimal S. Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. Mol Immunol. 2017 Feb;82:104-113. doi: 10.1016/j.molimm.2016.12.022. Epub 2017 Jan 5.

108
Vijayamahantesh, Amit A, Dikhit MR, Mishra A, Singh AK, Das VN, Das P and Bimal S. Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. Cytokine. 2017 Mar;91:170-179. doi: 10.1016/j.cyto.2017.01.001. Epub 2017 Jan 9.

107
Rabi Das VN, Siddiqui NA, Pal B, Lal CS, Verma N, Kumar A, Verma RB, Kumar D, Das P and Pandey K. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). PLoS One. 2017 Mar 29;12(3):e0174497. doi: 10.1371/journal.pone.0174497. eCollection 2017.

106
Vijayamahantesh, Amit A, Dikhit MR, Singh AK, Venkateshwaran T, Das VNR, Das P and Bimal S. Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects. Microbes Infect. 2017 Jun;19(6):358-369. doi: 10.1016/j.micinf.2017.03.002. Epub 2017 Apr 1.

105
Kumar R, Pandey K, Sahoo GC, Das S, Das V, Topno RK and Das P. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis. Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:1465-1471. doi: 10.1016/j.msec.2017.02.145. Epub 2017 Mar 4.

104
Das S, Sardar AH, Abhishek K, Kumar A, Rabidas VN and Das P. Cathelicidin augments VDR-dependent anti-leishmanial immune response in Indian Post-Kala-Azar Dermal Leishmaniasis. Int Immunopharmacol. 2017 Sep;50:130-138. doi: 10.1016/j.intimp.2017.06.010. Epub 2017 Jul 12.

103
Dikhit MR, Amit A, Singh AK, Kumar A, Mansuri R, Sinha S, Topno RK, Mishra R, Das VNR, Pandey K, Sahoo GC, Ali V, Bimal S and Das P. Vaccine potential of HLA-A2 epitopes from Leishmania Cysteine Protease Type III (CPC). Parasite Immunol. 2017 Sep;39(9). doi: 10.1111/pim.12451. Epub 2017 Jul 28.

102
Shivam P, Kumari S, Jamal F, Kumar V, Kumar M, Bimal S, Narayan S, Das VNR, Pandey K, Gupta AK, Das P and Singh SK. Leishmania donovani resistant to Ambisome or Miltefosine exacerbates CD58 expression on NK cells and promotes trans-membrane migration in association with CD2. Cytokine. 2017; 96:54-58. doi: 10.1016/j.cyto.2017.02.005. Epub 2017 Mar 16.

101
Pandey K, Pal B, Das VN, Murti K, Lal CS, Verma N, Bimal S, Ali V, Verma RB, Topno RK, Siddiqi NA and Das P. Safety and efficacy of a combination of Paromomycin and Miltefosine for two versus three courses in patients with Post Kala-Azar Dermal Leishmaniasis (PKDL) - an observational pilot Study. Br J Dermatol. 2017; 177(2):557-559. doi: 10.1111/bjd.15119. Epub 2017 Jul 2.

100
Jamal F, Shivam P, Kumari S, Singh MK, Sardar AH, Pushpanjali, Murugesan S, Narayan S, Gupta AK, Pandey K, Das VNR, Ali V, Bimal S, Das P and Singh SK. Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis. PLoS One. 2017 Aug 18;12(8):e0182474. doi: 10.1371/journal.pone.0182474. eCollection 2017.

99
Sinha KK, Peddada N, Jha PK, Mishra A, Pandey K, Das VN, Ashish and Das P. Plasma Gelsolin Level in HIV-1-Infected Patients: An Indicator of Disease Severity. AIDS Res Hum Retroviruses. 2017; 33(3): 254-260. doi: 10.1089/AID.2016.0154. (Epub 2016 Nov 3).

98
Amit A, Dikhit MR, Mahantesh V, Chaudhary R, Singh AK, Singh A, Singh SK, Das VN, Pandey K, Ali V, Narayan S, Sahoo GC, Das P and Bimal S. Immunomodulation mediated through Leishmania donovani protein disulfide isomerase by eliciting CD8+ T-cell in cured visceral leishmaniasis subjects and identification of its possible HLA class-1 restricted T-cell epitopes. J Biomol Struct Dyn. 2017; 35(1): 128-140. doi: 10.1080/07391102.2015.1134349.  (Epub 2016 Apr 12)

97

Paswan RK, Bimal S, Kumari A, Sinha P, Das VN, Pandey K, Kumar S, Verma RB, Das P and Lal CS. Reduced High Density Lipoprotein Concentration Modulates Increased Interleukin-10 and Decreased Interferon-Gamma in Visceral Leishmaniasis Patients. Gen Med (Los Angel) 2016; 4:233. doi:10.4172/2327-5146.1000233.

 

96
Scott J, Das VN and Siddiqui NA. Community-based Detection of Post Kala-azar Dermal Leishmaniasis (PKDL) and its Risk-Factors in an Endemic Region of Bihar, India. J Trop Dis 2016; 4:219. doi:10.4172/2329-891X.1000219

 

95
Jamal F, Dikhit MR, Singh MK, Shivam P, Kumari S, Pushpanjali, Dubey AK, Kumar P, Narayan S, Gupta AK, Pandey K, Das VN, Bimal S, Das P and Singh SK. Identification of B-Cell Epitope of Leishmania donovani and its application in Diagnosis of visceral leishmaniasis. J Biomol Struct Dyn. 2016 Nov 28:1-39. [Epub ahead of print]

94
Siddiqui NA, Rabidas VN, Sinha SK, Verma RB, Pandey K, Singh VP, Ranjan A, Topno RK, Lal CS, Kumar V, Sahoo GC, Sridhar S, Pandey A and Das P. Snowball Vs. House-to-House Technique for Measuring Annual Incidence of Kala-azar in the Higher Endemic Blocks of Bihar, India: A Comparison. PLoS Negl Trop Dis. 2016; 10(9): e0004970. doi: 10.1371/journal.pntd.0004970.

93
Das VN, Pandey RN, Siddiqui NA, Chapman LA, Kumar V, Pandey K, Matlashewski G and Das P. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS Negl Trop Dis. 2016; 10(12): e0005196. doi: 10.1371/journal.pntd.0005196.

92
Ejazi SA, Bhattacharya P, Bakhteyar MA, Mumtaz AA, Pandey K, Das VN, Das P, Rahaman M, Goswami RP and Ali N. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India. PLoS Negl Trop Dis. 2016; 10(10):e0005035. doi: 10.1371/journal.pntd.0005035.

91
Das S, Mandal R, Rabidas VN, Verma N, Pandey K, Ghosh AK, Kesari S, Kumar A, Purkait B, Lal CS and Das P. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study. PLoS Negl Trop Dis. 2016; 10(10): e0005060. doi: 10.1371/journal.pntd.0005060.

90
Vijayamahantesh, Amit A, Dikhit MR, Pandey RK, Singh K, Mishra R, Das VN, Das P and Bimal S. Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis in Indian Patients. PLoS One. 2016; 11(5): e0154117. doi: 10.1371/journal.pone.0154117.

89
Das VN, Pandey RN, Kumar V, Pandey K, Siddiqui NA, Verma RB, Matlashewski G and Das P. Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India. Pathog Glob Health. 2016; 110(1): 33-35. doi: 10.1080/20477724.2016.1156902.

88
Bhattacharya P, Ghosh S, Ejazi SA, Rahaman M, Pandey K, Ravi Das VN, Das P, Goswami RP, Saha B and Ali N. Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani. PLoS Negl Trop Dis. 2016; 10(2):e0004422. doi: 10.1371/journal.pntd.0004422.

87
Kumar R, Das VN, Topno RK, Pal B, Imam A, Agrawal K, Singh A, Murti K, Lal CS, Verma N, Das P and Pandey K. Para-kala-azar dermal Leishmaniasis cases in Indian subcontinent - A case series. Pathog Glob Health. 2016; 110(7-8): 326-329. No abstract available.

86
Pandey K, Ravidas V, Siddiqui NA, Sinha SK, Verma RB, Singh TP, Dhariwal AC, Das Gupta RK and Das P. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. Am J Trop Med Hyg. 2016; 95(5): 1100-1105.

85

Lal CS, Verma RB, Verma N, Siddiqui NA, Rabidas VN, Pandey K, Singh D, Kumar S, Paswan RK, Kumari A, Sinha P and Das P. Hypertriglyceridemia: a possible diagnostic marker of disease severity in visceral leishmaniasis. Infection. 2016; 44(1): 39-45. doi: 10.1007/s15010-015-0811-9. (Epub 2015 Jul 10).

84

Vijayamahantesh, Amit A, Kumar S, Dikhit MR, Jha PK, Singh AK, Sinha KK, Pandey K, Das VN, Das P and Bimal S. Up regulation of A2B adenosine receptor on monocytes are crucially required for immune pathogenicity in Indian patients exposed to Leishmania donovani. Cytokine. 2016; 79: 38-44. doi: 10.1016/j.cyto.2015.12.016. (Epub 2015 Dec 31).

83

Kumar R, Sahoo GC, Pandey K, Das VN, Topno RK, Ansari MY, Rana S and Das P. Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng C Mater Biol Appl. 2016; 59: 748-573. doi: 10.1016/j.msec.2015.10.083. (Epub 2015 Oct 29).

82

Verma N, Bimal S, Das VNR, Pandey K, Singh D, Lal CS, Singh AS, Sinha PK and Das P. Clinicopathological and Immunological Changes in Indian Post Kala-Azar Dermal Leishmaniasis (PKDL) Cases in relation to Treatment: A Retrospective Study. BioMed Research International 2015; Article ID 745062. http://dx.doi.org/10.1155/2015/745062

 

81

Kumari S, Jamal F, Shivam P, Thakur A, Kumar M, Bimal S, Das VN, Pandey K, Narayan S, Gupta AK, Das P and Singh SK. Leishmania donovani skews the CD56(+) Natural Killer T cell response during human visceral leishmaniasis. Cytokine. 2015; 73(1): 53-60. doi: 10.1016/j.cyto.2015.01.011. (Epub 2015 Feb 16).

80

Yadav A, Amit A, Chaudhary R, Chandel AS, Mahantesh V, Suman SS, Singh SK, Dikhit MR, Ali V, Rabidas V, Pandey K, Kumar A, Das P and Bimal S. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis. Int J Parasitol. 2015; 45(1): 33-42. doi: 10.1016/j.ijpara.2014.08.013. (Epub 2014 Oct 15).

79

Das P, Amit A, Singh SK, Chaudhary R, Dikhit MR, Yadav A, Pandey K, Das VN, Sundram S, Das P and Bimal S. Leishmania donovani phosphoproteins pp41 and pp29 re-establishes host protective immune response in visceral leishmaniasis. Parasitol Int. 2015; 64(1): 18-25. doi: 10.1016/j.parint.2014.08.004. (Epub 2014 Sep 16).

78

Pandey K, Singh D, Bimal S, Rabidas V, Murti K, Lal CS and Das P. Newer drugs for Visceral Leishmaniasis: a review. American Journal of Infectious Diseases, 2014; 10 (2): 68-70.

 

77

Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S and Das P. Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study. PLoS Negl Trop Dis. 2014; 8(9): e3169. doi: 10.1371/journal.pntd.0003169.

76

Das VNR, Singh D, Murti K, Das S, Das P and Pandey K. Post Kala-azar Dermal Leishmaniasis with ulceration on foot: An atypical case presentation successfully treated with miltefosine. American Journal of Infectious Diseases, 2014; 10(2): 50-55.

 

75

Das S, Halder A, Rabidas VN, Mandal A and Das P. Specific noninvasive detection of Leishmania donovani in desquamated buccal cell swab samples from human visceral Leishmaniasis-HIV coinfected patients. J Clin Microbiol. 2014; 52(4): 1238-1241. doi: 10.1128/JCM.02819-13.

74

Murhekar MV, Ahmad M, Shukla H, Abhishek K, Perry RT, Bose AS, Shimpi R, Kumar A, Kaliaperumal K, Sethi R, Selvaraj V, Kamaraj P, Routray S, Das VN, Menabde N and Bahl S. Measles Case Fatality Rate in Bihar, India, 2011–12. PLoS One. 2014; 9 (5): e96668.

73

Das VN, Pandey RN, Pandey K, Singh V, Kumar V, Matlashewski G and Das P. Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. PLoS Negl Trop Dis. 2014; 8 (5): e2774.

72

Amit A, Chaudhary R, Yadav A, Suman SS, Narayan S, Das VN, Pandey K, Singh SK, Singh BK, Ali V, Das P and Bimal S. Evaluation of Leishmania donovani disulfide isomerase as a potential target of cellular immunity against visceral leishmaniasis. Cell Immunol. 2014; 289(1-2): 76-85. doi: 10.1016/j.cellimm.2014.03.011.

71

Das S, Rani M, Rabidas V, Pandey K, Sahoo GC and Das P. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin–miltefosine combination therapy in visceral leishmaniasis. British Journal of Pharmacology. 2014; 171: 1260–1274.

 

70

Chaudhary R, Amit A, Yadav A, Singh A, Kumar V, Singh SK, Narayan S, Rabidas V, Pandey K, Kumar A, Das P and Bimal S. Immunomodulation in Human Dendritic Cells Leads to Induction of Interferon-Gamma Production by Leishmania donovani Derived KMP-11 Antigen via Activation of NF-κB in Indian Kala-Azar Patients. Biomed Res Int. 2014; 2014: 947606. doi: 10.1155/2014/947606.

69

Kumar V, Bimal S, Singh SK, Chaudhary R, Das S, Lal C, Pandey K, Das VR and Das P. Leishmania donovani: Dynamics of L. donovani evasion of innate immune cell attack due to malnutrition in visceral leishmaniasis. Nutrition. 2014; 30(4): 449-458.

68

Pandey K, Singh D, Das VR, Bimal S, Singh BK and Das P. Progressive Multifocal Leukoencephalopathy Associated with Pulmonary Tuberculosis in an Immuno-Compromised Indian Patient. J AIDS Clin Res. 2013; 4: 9. http://dx.doi.org/10.4172/2155-6113.1000241.

 

67

Verma N, Singh D, Pandey K, Das VN, Lal CS, Verma RB, Sinha PK and Das P. Comparative Evaluation of PCR and Imprint Smear Microscopy of Skin Biopsy in Diagnosis of Macular, Papular and Mixed Papulo-nodular Lesions of PKDL. J Clin Microbiol. 2013; 51(12): 4217-4219. doi: 10.1128/JCM.01482-13. (Epub 2013 Sep 25).

66

Shivam P, Jamal F, Kumari S, Bimal S, Narayan S, Das VN, Pandey K, Gupta AK, Singh D, Verma N, Das P and Singh SK. Leishmania donovani: Influence of anti-leishmanial therapy on expression of lymphocyte function-associated antigen-3 and its relevance to pathogenisis in visceral leishmaniasis. Hum Immunol. 2013; 74(12): 1575-1578. doi: 10.1016/j.humimm.2013.08.007. (Epub 2013 Aug 20).

65

Pandey K, Singh D, Lal C S, Das V, Das P. Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment. J Postgrad Med. 2013; 59(4): 306-308. doi: 10.4103/0022-3859.123161.

64
Das S, Pandey K, Rabidas VN, Mandal A and Das P. Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients. J Antimicrob Chemother. 2013; 68(9): 2059-2065. doi: 10.1093/jac/dkt162. (Epub 2013 May 31).
63
Thakur AK, Bimal S, Singh SK, Gupta AK, Das VN, Das P and Narayan S. Degree of anemia correlates with increased utilization of heme by Leishmania donovani parasites in visceral leishmaniasis. Exp Parasitol. 2013; 135(3): 595-598. doi: 10.1016/j.exppara.2013.09.008.
62

Matlashewski G, Pandey R, Das V and Das P. One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done? PLoS Negl Trop Dis. 2013; 27: 7(6): e2082.

61

Matlashewski G, Das VN, Pandey K, Singh D, Das S, Ghosh AK, Pandey RN and Das P. Diagnosis of visceral leishmaniasis in Bihar India: comparison of the rK39 rapid diagnostic test on whole blood versus serum. PLoS Negl Trop Dis. 2013; 23: 7(5): e2233.

60

Verma N, Lal CS, Rabidas V, Pandey K, Singh D, Kumar S, Verma RB and Das P. Microalbuminuria and glomerular filtration rate in paediatric visceral leishmaniasis. Biomed Res Int. 2013; 2013: 498918. doi: 10.1155/2013/498918. (Epub 2013 Jun 23).

59

Das V, Pandey K, Singh D, Forwood C, Lal CS and Das P. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India. J Postgrad Med. 2013; 59(3): 226-228. doi: 10.4103/0022-3859.118046.

58

Lal CS, Kumar S, Ranjan A, Rabidas VN, Verma N, Pandey K, Verma RB, Das S, Singh D and Das P. Comparative analysis of serum zinc, copper, magnesium, calcium and iron level in acute and chronic patients of visceral leishmaniasis. J Trace Elem Med Biol. 2013; 27(2): 98-102. doi: 10.1016/j.jtemb.2012.09.007. (Epub 2012 Nov 28).

57

Singh D, Pandey K, Das VN, Das S, Verma N, Ranjan A, Lal CS, Topno KR, Singh SK, Verma RB, Kumar A, Sardar AH, Purkait B and Das P. Evaluation of rK-39 Strip Test Using Urine for Diagnosis of Visceral Leishmaniasis in an Endemic Region of India.  Am Am J Trop Med Hyg. 2013; 88(2): 222-226. doi: 10.4269/ajtmh.2012.12-0489. (Epub 2012 Nov 13).

56

Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J and Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health. 2013; 18(1): 96-100. doi: 10.1111/tmi.12015. ( Epub 2012 Nov 8).

 

55

Das S, Pandey K, Kumar A, Sardar AH, Purkait B, Kumar M, Kumar S, Ravidas VN, Roy S, Singh D and Das P. TGF-β(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol. 2012; 90(6): 640-654. doi: 10.1038/icb.2011.80. ( Epub 2011 Oct 4).

54

Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D and Das P. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012; 56(2): 1031-1041. doi: 10.1128/AAC.00030-11. (Epub 2011 Nov 28).

53

Das S, Rani M, Pandey K, Sahoo GC, Rabidas VN, Singh D and Das P. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. J Antimicrob Chemother. 2012; 67(10): 2373-2378. (Epub 2012 Jul 3).

52

Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, Verma N, Ranjan A, Sinha PK, Das VN, Pandey K, Kar SK and Das P. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection. Exp Parasitol. 2012; 131(3): 274-282. (Epub 2012 May 10).

51

Das VNR, Ranjan A, Pandey K, Singh D, Verma N, Das S, Lal CS, Sinha NK, Verma RB, Siddiqui NA, and Das P. Short Report: Clinico-Epidemiologic Profile of a Cohort of Post–Kala-Azar Dermal Leishmaniasis Patients in Bihar, India. Am. J. Trop. Med. Hyg., 2012; 86(6): 959–961.

50

Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK and Das P. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J Clin Microbiol. 2012; 50(4): 1478-1479. (Epub 2012 Jan 25).

49

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H and Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg, 2011; 105(2): 115-117 (Epub 2010 Dec 3).

48

Wairagkar N, Chowdhury D, Vaidya S, Sikchi S, Shaikh N, Hungund L, Tomar RS, Biswas D, Yadav K, Mahanta J, Das VN, Yergolkar P, Gunasekaran P, Raja D, Jadi R, Ramamurty N, Mishra AC and MeaslesNetIndia collaborators. Molecular Epidemiology of Measles in India, 2005–2010. J Infect Dis., 2011; 204(suppl 1): S403-S413.

47

Ghosh J, Lal CS, Pandey K, Das VN, Das P, Roychoudhury K and Roy S. Human visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load. Ann Trop Med Parasitol., 2011; 105(3): 267-271.

46

Das S, Pandey K, Kumar A, Sardar AH, Purkait B, Kumar M, Kumar S, Ravidas VN, Roy S, Singh D and Das P. TGF-β(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol, 2011; Oct 4. doi: 10.1038/icb. 2011.80. [Epub ahead of print].

45

Das VN, Siddiqui NA, Verma RB, Topno RK, Singh D, Das S, Ranjan A, Pandey K, Kumar N and Das P. Asymptomatic infection of visceral leishmaniasis in hyperendemic areas of Vaishali district, Bihar, India: a challenge to kala-azar elimination programmes. Trans R Soc Trop Med Hyg, 2011; 105(11): 661-666. (Epub 2011 Sep 25).

44

Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D and Das P. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Chemother. 2011 Nov 28. [Epub ahead of print]

43

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F and Pandey K. Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India. Am J Trop Med Hyg. 2010; 83(2): 357-364.

42

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H and Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg, 2011; 105(2): 115-7 (Epub 2010 Dec 3).

41

Topno RK, Das VN, Ranjan A, Pandey K, Singh D, Kumar N, Siddiqui NA, Singh VP, Kesari S, Kumar N, Bimal S, Kumar AJ, Meena C, Kumar R and Das P. Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg. 2010; 83(3): 502-506

40

Das VNR, Pandey K, Verma N, Bimal S, Lal CS, Singh D and Das P. Post-kala-azar dermal leishmaniasis(PKDL), HIV and pulmonary tuberculosis . National Medical Journal of India. 2010; 23(2): 88-89.

 

39

Siddiqui NA, Kumar N, Ranjan A, Pandey K, Das VNR, Verma RB and Das P. Awareness about Kala-azar disease and related preventive attitudes and practices in a highly endemic rural area of India.  Southeast Asian journal of tropical medicine and public health .2010; 41(1): 1-12.

 

38

Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, Kumar N, Pandey K and Das P. Estimation of under reporting of Visceral Leishmaniasis cases in Bihar, India. . American Journal of Tropical Medicine Hygiene .2010; 82(1): 9-11.


37

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB and Das P. Development of Post Kala-Azar Dermal Leishmaniasis (PKDL) in Miltefosinetreated visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene, 2009; 80(3): 336-338.


36

Banerjee S, Ghosh J, Sen S, Guha R, Dhar R, Ghosh M, Datta S, Raychaudhury B, Naskar K, Haldar AK, Lal CS, Pandey K, Das VN, Das P and Roy S. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infection and immunity, 2009, 77(6): 2330-2342.


35

Das VN, Siddiqui NA, Pandey K, Singh VP, Topno RK, Singh D, Verma RB, Ranjan A, Sinha PK and Das P. A controlled, randomized nonblinded clinical trial to assess the effi cacy of  mphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Therapeutics and Clinical Risk Management, 2009; 5: 117–124.


34

Singh D, Pandey K, Das VN, Das S, Kumar S, Topno RK and Das P. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. J Clin Microbiol. 2009; 47(8): 2684-2685.

33

Pandey K, Sinha PK, Das VN, Bimal S, Singh SK and Das P. Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario. Clinical Medicine: Pathology, 2009; 2: 1–4.

 

32

Pandey K, Sinha PK, Das VN, Nawin Kumar, Bimal S, Verma RB, Verma N, Lal CS, Topno RK, Siddiqui NA, Singh D and Das P.Tuberous sclerosis with visceral leishmaniasis: a case report. Journal of Medical Case Reports, 2009; 3: 9027.

31

Kesari S,Kumar V,Palit A, Kishore K, Das VNR, Das P,and Bhattacharya SK. Localilized Foci of kala-azar in a Village of Chandi PHC (Nalanda District ),Journal of Communucable Diseases., 2009; 41(3) 211-214

 

30

Kumar N, Pandey K, Das VN, Sinha PK, Topno RK, Lal CS, Bimal S, Verma N and Das P. HIV infection, visceral leishmaniasis and Guillain –Barre syndrome in same patient: a case report. Ann. Trop. Med. & Parasitol., 2008; 102(2): 185-188.

29

Topno RK, Pandey K, Das VN, Kumar N, Bimal S, Verma RB, Siddiqui NA, Singh D, Kumar R, Kumar P, Ranjan A, Das P and Sinha PK. Visceral Leishmaniasis in pregnancy – role of Amphotericin B. Ann. Trop. Med. & Parasitol, 2008; 102(3): 267-270.

28

Kumar N, Pandey K, Das VN, Sinha PK, Topno RK, Verma N, Lal CS, Das P and Bhattacharya SK. Miltefosine in the Treatment of a case of Visceral Leishmaniasis with Renal Dysfunction. Ann Trop Med Parasitol, 2007; 101(7): 649-651.

27

Pandey K, Sinha PK, Das VN, Kumar N, Verma N, Bimal S, Lal CS, Topno RK, Singh D, Verma RB, Bhattacharya SK and Das P.Wilson Disease with Visceral Leishmaniasis: An Extremely Uncommon Presentation. Am J Trop Med Hyg. 2007; 77(3): 560 – 561.

26

Das VN, Siddiqui NA, Kumar N, Verma N, Verma RB, Dinesh DS, Kar SK and Das P . A pilot study on the status of lymphatic filariasis in a rural community of Bihar. J Commun Dis., 2006; 38(2): 169-75.


25

Sinha PK, Ranjan A, Singh VP, Das VNR, Pandey K, Kumar N, Verma N, Lal CS, Sur D, Manna B and Bhattacharya SK. Visceral Leishmaniasis (Kala-azar)-the Bihar (India) perspective. J Infect. 2006; 53(1): 60-64.

24

Das VN, Siddiqui NA, Kumar N, Verma N, Verma RB, Dinesh DS, Kar SK and Das P. Preliminary evidence on existence of transplasma membrane electron transport in Entamoeba histolytica trophozoites: a key mechanism for maintaining optimal redox balance. J Bioenerg Biomembr. 2006; 38(5-6): 299-308.


23

Das VN, Pandey K, Kumar N, Hassan SM, Bimal S, Lal CS, Siddiqui NA and Bhattacharya SK. Visceral leishmaniasis and tuberculosis in patients with HIV co-infection. Southeast Asian J Trop Med Public Health, 2006; 37(1): 18-21.


22

Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK and Bhattacharya SK. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.Natl Med J India, 2005; 18(3): 131-133.


21

Bimal S, Das VN, Sinha PK, Gupta AK, Verma N, Ranjan A, Singh SK, Sen A, Bhattacharya SK and Das P. Usefulness of the direct agglutination test in the early detection of subclinical L.  donovani infection: a community-based study. Ann. Trop. Med. & Parasitol., 2005; 99: 743-749.

20

Bimal S, Singh SK, Das VN, Sinha PK, Gupta AK, Bhattacharya SK and Das P. Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis. Exp Parasitol. 2005; 111(2): 130-132.

19

Das VNR, Pandey K, Kumar N, Hassan SM, and Bhattacharya SK. HIV Infection, Pneumonic Patch with Tuberculosis and Hepatitis- A case Report. Journal of communicable Diseases. 2005; 37(2): 155-157.

18

Pandey K, Sinha PK, Das VN, Kumar N, Hassan SM, Verma N, Lal CS, Bimal S, Das P and Bhattacharya SK. HIV-I infection, visceral leishmaniasis, Koch's chest and tuberculous meningitis in the same patient- a case report. Ann Trop Med Parasitol. 2005; 99(8): 807-811.

17

Pandey K, Sinha PK, Das VNR, Sur D, Kumar Nawin, and Bhattacharya SK. Neurocysticercosis in a Patient With Visceral Leishmaniasis Co-infected With HIV: A Case Report. Infectious Disease in Clinical Practice. 2005; 13(3): 1-2.

 

16

Lal CS, Kumar V, Ranjan A, Das VN, Kumar N, Kishore K and Bhattacharya SK. Evaluation of Cholinesterase level in an endemic population exposed to Malathion Suspension Formulation as a vector control measure. Memorias Do Instituto Oswaldo Cruz, 2004; 99(2): 219-221.


15

Bimal S, Das VNR, Sinha PK, Gupta AK, Verma N, Ranjan A, Singh SK, Bhattacharya SK and Pas P. Relevance of direct agglutination test for detection of sub-clinical infection among contacts of kala-azar and non- kala-azar households. J Immunol Immunopathol. 2004; 6(S-1): 85.      

 

14

Sinha PK, RabiDas VN, Pandey K, Verma N, Gupta AK, Ranjan A, Das P and Bhattacharya SK. Visceral Leishmaniasis and HIV Coinfection in Bihar, India. Letter to Editor, J Acquire Immune Defic Syndr. 2003; 32(1): 115-116.


13

Kumar N, Siddiquiu NA, Verma RB, RabiDas VNR, Verma N and Kar SK .A pilot study on mother's knowledge and their perception about control, transmission and treatment of Lymphatic Filariasis in a rural community of Bihar.Journal of Parasitic Diseases, 2003; 27: 33-37.

 

12

Das VN, Dinesh DS, Verma N and Kar SK.A case report on self-cure of visceral leishmaniasis .J Commun Dis.2002; 34(4): 302-203.

11

Verma N, Bimal S, Gupta AK, Das VNR, Kar SK and Bhattacharya SK. Imunohistochemical staining of dermal lesions in diagnosis of Post Kala-azar Dermal leishmaniasis (PKDL) in compare to Biopsy Imprint Smear & Culture. Jour. of Lab. Med.,2002; 3(1): 41-42.

 

10

Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, Siddiqui NA and Kar SK. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.Journal of Association of Physician of India, 2001; 49: 609-613.

9

Kumar V, Kishore K, Palit A, Keshari S, Sharma MC, Das VN, Shivakumar S, Roy MS, Sinha NK, Prasad M and Kar SK. Vectorial efficacy of Phlebotomus argentipes in Kala-azar endemic foci of Bihar (India) under natural and artificial conditions. J Commun Dis. 2001; 33(2): 102-109.

8

Verma N, Sinha SP, Das VNR and Kar SK. Erythropoiesis in relation to anaemia in Kala-azar. Journal of Parasitic Diseases, 2001; 25(1): 40-41.

7

Sharma MC, Bimal S, Ranjan A, Das VN, Gupta AK, Kumar N and Kar SK. Relevance of direct agglutination test in sero-epidemiological survey of kala-azar in epidemic foci of Bihar.Journal of Communicable Diseases. 2000; 32(2): 117-122.

6

Sharma MC, Gupta AK, Verma N, Das VN, Saran R and Kar SK. Demonstration of Leishmania parasite in skin lesions of Indian post kala-azar dermal leishmaniasis. Journal of Communicable Diseases. 2000; 32(1): 67-68.

5

Sharma MC, Gupta AK, Das VN, Verma N, Kumar N, Saran R and Kar SK. Leishmania donovani in blood smears of asymptomatic persons.  Acta Trop. 2000; 76(2): 195-196.

4

Ranjan A, Kumar N, Das VNR, Palit A, Kishore K, Bimal S, Siddique NA, Singh VP and Kar SK. Epidemiological Parameters in Epidemic and Endemic areas of Visceral Leishmaniasis in Bihar, India. Journal of Parasitic Diseases 2000: 24(2): 223-225.

3

Dinesh DS, Das VNR, Palit A, Kishore K, Verma N, Gupta AK, Sharma MC, Kumar N. and Kar, SK. The role of Post Kala-azar Dermal Leishmaniasis in the transmission of Visceral Leishmaniasis through Phlebotomus Argentipes. Tropical Biomedicine. 2000; 17: 7.

 

2

Lal CS, Gupta AK, Das VNR, Verma N, Sinha NK, Singh R, Palit A and Kar SK. Isoenzyme typing of Leishmania parasites in different geographical distribution in Bihar. Journal of Parasitic Diseases, 1999; 23(1): 27.

 

1

Dinesh DS, Das VNR, Kishore K, Palit A and Kar SK. Vectorial capacity of sandflies in correlation with cases of Kala-azar in an endemic focus of Bihar. Journal of Parasitic Diseases, 1999; 23(1). 57.